About Lantheus Holdings, Inc. - Common Stock (LNTH)
Lantheus Holdings is a biotechnology company that specializes in developing and commercializing innovative diagnostic imaging agents and therapeutics primarily for oncology and other conditions. Their products include advanced molecular imaging agents that enhance the visualization of diseases in patients, enabling healthcare providers to make more informed decisions about diagnosis and treatment. The company is committed to advancing patient care through its focus on precision medicine, utilizing cutting-edge technologies to improve the detection and management of various diseases, particularly cancers, thus helping clinicians optimize patient outcomes. Read More
LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK - November 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. (NASDAQ: LNTH) of a class action securities lawsuit.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) announced better-than-expected revenue in Q3 CY2025, with sales up 1.4% year on year to $384 million. The company’s full-year revenue guidance of $1.5 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.27 per share was in line with analysts’ consensus estimates.
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, inclusive.
BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2025.
NEW YORK - November 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. (NASDAQ: LNTH) of a class action securities lawsuit.
NEW YORK - November 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. (NASDAQ: LNTH) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Lantheus To Contact Him Directly To Discuss Their Options
Lantheus Holdings (LNTH) appears undervalued with strong fundamentals. Its low P/E ratio, robust profitability, and healthy balance sheet make it a compelling value investing candidate.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options
LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
NEW YORK - October 31, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. (NASDAQ: LNTH) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options
LOS ANGELES, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
